News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
OncoArendi Therapeutics announced today that it has filed a Clinical Trial Application (CTA)
7 July 2017
OncoArendi Therapeutics Announces Selection of Its Second Clinical Development Candidate: OATD-02 For the Treatment of Multiple Cancers
21 June 2017
OncoArendi raises 4.5 mln USD (18 million PLN) in an extension of Series A financing round
8 March 2017
OncoArendi receives the President’s Economic Award as the best Polish R&D Company in 2016
17 November 2016
OncoArendi Therapeutics has entered into a global license agreement with Yale University
10 February 2015